Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Chronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomy

F. Couturaud, I. Frachon, C. Leroyer
European Respiratory Journal 2009 33: 230-232; DOI: 10.1183/09031936.00175508
F. Couturaud
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Frachon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Leroyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Our understanding of chronic thromboembolic pulmonary hypertension (CTEPH), in terms of both its natural history and pathophysiology, has greatly improved since the landmark descriptions given by Moser and Braunwald 1 more than 40 yrs ago. At that time, small case series were available, depicting the clinical features of patients suffering from “long-standing thromboembolic pulmonary hypertension”, “chronic massive thromboembolic obstruction” or “chronic obstruction of large pulmonary arteries”. These patients shared a history of long-term dyspnoea on exertion with normal spirometry values, evidence of pulmonary hypertension, and right ventricular dysfunction in association with the presence of marked defects at the ventilation/perfusion scan; the occurrence of a single or multiple venous thromboembolism episodes, usually several years previously, was constantly mentioned in the diagnostic work-up 2–5. The success of a surgical procedure, namely pulmonary endarterectomy, has transformed this lethal disorder into a potentially curable form of pulmonary hypertension 1. As a consequence, the referral of cases suitable for surgery has gradually increased with time: at the University of San Diego (San Diego, CA, USA) there were 41 operated cases in 1980, rising to 323 cases in 1992 6, 7. This has enabled us to broaden our knowledge, with the help of further involvement from European centres 8–11].

Forty years ago, the frequency of CTEPH was estimated to be 0.1% of patients who survived an episode of pulmonary embolism 12. Keeping in mind that an accurate estimation of the true frequency of CTEPH cannot be appraised by such case studies, researchers designed prospective descriptive follow-ups of patients recovering from an acute episode of pulmonary embolism. In the study by Ribeiro et al. 13, systolic pulmonary arterial pressure, as estimated by echocardiography, exceeded 30 mmHg at 1 yr in 34 out of 78 patients, and a pulmonary endarterectomy was indicated in three of the patients at 12, 24 and 44 months. In the largest published prospective cohort, Pengo et al. 14 followed-up pulmonary embolism patients every 6 months during the first 2 yrs; patients with unexplained dyspnoea at rest or on exertion underwent echocardiography and CTEPH was considered to be present if the systolic and mean pulmonary artery pressures exceeded 40 and 25 mmHg, respectively. Based on this screening, Pengo et al. 14 found a cumulative incidence of symptomatic CTEPH of 3.8% at 2 yrs (95% confidence interval (CI) 1.1–6.5). These data suggested that CTEPH following acute pulmonary embolism is much more common than was previously reported 15.

Data from patients referred for possible pulmonary endarterectomy have not shown a systematic link between acute pulmonary embolism and CTEPH, as a documented history of prior venous thromboembolism events is missing in about 50% of CTEPH cases from such series 16. Although possible asymptomatic pulmonary embolism cannot be excluded, the unique embolic origin of CTEPH has thus been questioned. This disturbing finding, in addition to the histopathological evidence of in situ arteriopathic changes in the resistance vessels of both involved and uninvolved pulmonary vascular areas, has prompted researchers to study overlapping of histopathology, predisposing factors, clinical signs and symptoms between CTEPH and idiopathic pulmonary arterial hypertension 12. An original depiction of CTEPH has emerged, individual to that of idiopathic pulmonary arterial hypertension or of a venous thromboembolic disease.

A better understanding of this complex field is provided by two original contributions published in the current issue of the European Respiratory Journal. Bonderman et al. 17 gathered data retrospectively from three European referral centres for CTEPH covering four countries (Austria, Czech Republic, Germany and Slovak Republic). They compared 433 CTEPH cases with 254 non-thromboembolic pulmonary arterial hypertension patients from the same centres. Besides previously identified conditions associated with CTEPH, such as splenectomy or ventriculo-atrial shunt (both risk factors showing the highest odds ratios (ORs)), two possible associated conditions emerged, namely thyroid replacement therapy (OR 6.10, 95% CI 2.73–15.05) and history of malignancy (OR 3.76, 95% CI 1.47–10.43). The authors also found higher than previously published reported rates of history of and recurrence of venous thromboembolism (69 and 52%, respectively) in CTEPH patients.

The contribution of Condliffe et al. 18 is based on the CTEPH UK national registry. The authors retrieved data regarding 236 patients who underwent pulmonary endarterectomy and 148 nonoperable patients; the main objective was to assess predictors of survival in both groups. In the operable patients, gas transfer and exercise capacity emerged as potential predictors, together with pulmonary resistance, a previously underlined prognostic factor. In the nonoperable patients, cardiac index and exercise capacity were the independent predictors. Among the previously described clinical risk factors for the development of CTEPH, interestingly enough, the history of venous thromboembolism was significantly less frequent in nonoperable patients than in patients who underwent pulmonary endarterectomy (49 versus 62%; p = 0.01), supporting the hypothesis that in a certain number of patients a process of in situ thrombosis may occur.

Given the rich body of data gathered by these partly retrospective studies, the next step is a prospective one: the authors involved in these two studies are now involved in the recently launched international registry on CTEPH, the first collaborative work which aims to improve our understanding of the disease on a large scale 19. This prospective observational registry will identify potential risk factors, characterise CTEPH history and evaluate long-term survival. The heterogeneity of CTEPH will thus be explored in depth. The history of venous thromboembolism, using a validated and standardised questionnaire based on the clinical symptoms of pulmonary embolism, the results of investigations and the duration of anticoagulation with respect to a reported episode deserve special attention 20. Thanks to the recent fundamental outbreaks in the field of pulmonary arterial hypertension, the identification of cellular, molecular and genetic mechanisms will be facilitated 21. An adequate assessment of patients who might benefit from endarterectomy, as well as of those who might benefit from medical treatment will be performed. Randomised trials comparing different therapeutic strategies in well-classified patients will be possible subsequently.

Another line of research could be undertaken through exploration of the underlined links between chronic thromboembolic pulmonary hypertension and the history of venous thromboembolism 15. Cohort studies of unselected patients recovering from a proven episode of acute pulmonary embolism have the potential to adequately assess the incidence rate of chronic thromboembolic pulmonary hypertension. If confirmed, the fairly high chronic thromboembolic pulmonary hypertension incidence rate in patients with pulmonary embolism might set a new therapeutic challenge; until recently, the main end-points when evaluating different treatment regimens with respect to an acute episode of pulmonary embolism, in terms of the duration of anticoagulation or the types of molecules (new anticoagulant, fibrinolytics etc.), were recurrent venous thromboembolism episodes and major bleedings 22, 23. It is also worth considering the occurrence of chronic thromboembolic pulmonary hypertension in the benefit–risk balance of anticoagulant therapy. Careful referral to specialised centres and inclusion in the international registry, as well as the long-term follow-up of patients recovering from acute pulmonary embolism are complementary approaches towards a better understanding of this intriguing disease.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Moser KM, Braunwald NS. Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest 1973;64:29–35.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Ball KP, Goodwin JF, Harrison CV. . Massive thrombotic occlusion of the large pulmonary arteries. Circulation 1956;14:766–783.
      OpenUrlAbstract/FREE Full Text
    3. Carroll D. Chronic obstruction of major pulmonary arteries. Am J Med 1950; 9: 175–185
    4. Moser KM, Rhodes PG, Hufnagel CC. Chronic unilaterel pulmonary artery thrombosis: successful thromboendartectomy with thirty-month follow-up observation. N Engl J Med 1965;272:1195–1199.
      OpenUrlPubMed
    5. ↵
      Moser KM, Houk VN, Jones RC, Hufnagel CC. Chronic, massive thrombotic obstruction of the pulmonary arteries. Analysis of four operated cases. Circulation 1965;32:377–385.
      OpenUrlAbstract/FREE Full Text
    6. ↵
      Daily PO, Dembitsky WP, Peterson KL, Moser KM. Modifications of techniques and early results of pulmonary thromboendarterectomy for chronic pulmonary embolism. J Thorac Cardiovasc Surg 1987;93:221–233.
      OpenUrlPubMedWeb of Science
    7. ↵
      Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J 1992;5:334–342.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005;93:512–516.
      OpenUrlPubMedWeb of Science
    9. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1122–1127.
      OpenUrlCrossRefPubMedWeb of Science
    10. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:637–648.
      OpenUrlAbstract/FREE Full Text
    11. ↵
      Lang IM. Chronic thromboembolic pulmonary hypertension. Indian Heart J 1999;51:27–30.
      OpenUrlPubMed
    12. ↵
      Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345:1465–1472.
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation 1999;99:1325–1330.
      OpenUrlAbstract/FREE Full Text
    14. ↵
      Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257–2264.
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc 2006;3:564–567.
      OpenUrlCrossRefPubMed
    16. ↵
      Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:608–614.
      OpenUrlCrossRefPubMed
    17. ↵
      Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33: 325–331
    18. ↵
      Condliffe R, Kiely DG, Gibbs JSR, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33: 332–337
    19. ↵
      Simonneau G, Delcroix M, Mayer E, Lang I, Pepke-Zaba J. First international registry on chronic thromboembolic pulmonary hypertension. Eur Respir J 2008;32: Suppl. 52 174s
      OpenUrl
    20. ↵
      Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996;143:1257–1265.
      OpenUrlAbstract/FREE Full Text
    21. ↵
      Sacks RS, Remillard CV, Agange N, Auger WR, Thistlethwaite PA, Yuan JX. Molecular biology of chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg 2006;18:265–276.
      OpenUrlCrossRefPubMed
    22. ↵
      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College Of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133: Suppl. 6 454S–545S.
      OpenUrlCrossRefPubMedWeb of Science
    23. ↵
      Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358:1037–1052.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 33 Issue 2 Table of Contents
    European Respiratory Journal: 33 (2)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Chronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomy
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Chronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomy
    F. Couturaud, I. Frachon, C. Leroyer
    European Respiratory Journal Feb 2009, 33 (2) 230-232; DOI: 10.1183/09031936.00175508

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Chronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomy
    F. Couturaud, I. Frachon, C. Leroyer
    European Respiratory Journal Feb 2009, 33 (2) 230-232; DOI: 10.1183/09031936.00175508
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • GM-CSF targeting in COVID-19, an approach based on fragile foundations
    • Short and Long Term Non-Invasive Cardiopulmonary Exercise Assessment in previously Hospitalized COVID-19 Patients
    • Commemorating World Tuberculosis Day 2022
    Show more Editorial

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society